- Home
- TYRA vs TCPC Comparison
TYRA vs TCPC Comparison
Compare TYRA & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- TCPC
- Stock Information
- Founded
- TYRA 2018
- TCPC 2012
- Country
- TYRA United States
- TCPC United States
- Employees
- TYRA 38
- TCPC N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- TCPC Finance/Investors Services
- Sector
- TYRA Health Care
- TCPC Finance
- Exchange
- TYRA Nasdaq
- TCPC Nasdaq
- Market Cap
- TYRA 666.4M
- TCPC 767.3M
- IPO Year
- TYRA 2021
- TCPC 2012
- Fundamental
- Price
- TYRA $13.17
- TCPC $9.45
- Analyst Decision
- TYRA Strong Buy
- TCPC Hold
- Analyst Count
- TYRA 6
- TCPC 7
- Target Price
- TYRA $30.50
- TCPC $8.88
- AVG Volume (30 Days)
- TYRA 247.2K
- TCPC 483.1K
- Earning Date
- TYRA 03-18-2025
- TCPC 02-27-2025
- Dividend Yield
- TYRA N/A
- TCPC 18.66%
- EPS Growth
- TYRA N/A
- TCPC N/A
- EPS
- TYRA N/A
- TCPC N/A
- Revenue
- TYRA N/A
- TCPC $249,036,775.00
- Revenue This Year
- TYRA N/A
- TCPC $27.36
- Revenue Next Year
- TYRA N/A
- TCPC N/A
- P/E Ratio
- TYRA N/A
- TCPC N/A
- Revenue Growth
- TYRA N/A
- TCPC 21.38
- 52 Week Low
- TYRA $11.89
- TCPC $7.71
- 52 Week High
- TYRA $29.60
- TCPC $11.52
- Technical
- Relative Strength Index (RSI)
- TYRA 43.64
- TCPC 64.22
- Support Level
- TYRA $12.27
- TCPC $9.30
- Resistance Level
- TYRA $13.79
- TCPC $9.47
- Average True Range (ATR)
- TYRA 0.71
- TCPC 0.14
- MACD
- TYRA 0.03
- TCPC 0.03
- Stochastic Oscillator
- TYRA 51.09
- TCPC 94.44
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.